![](https://investorshub.advfn.com/uicon/335383.png?cb=1609924894)
Wednesday, April 23, 2014 7:55:30 AM
OncoGenex Announces Fast Track Designation Granted for Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Phase 3 AFFINITY Trial of Men with Metastatic Castrate-Resistant Prostate Cancer
1 hours 52 minutes ago - DJNF
Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation
BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following prior treatment with a docetaxel-containing regimen.
Fast track is a process designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.
The international, randomized, open-label Phase 3 AFFINITY trial is designed to evaluate if custirsen, when combined with second-line chemotherapy cabazitaxel and prednisone, has the potential to improve survival outcomes for prostate cancer patients compared to second-line chemotherapy alone. AFFINITY will enroll approximately 630 men and is expected to complete enrollment in the second half of 2014.
Custirsen has also received Fast Track designation from the FDA for treatment of patients with metastatic non-small cell lung cancer as part of the Phase 3 ENSPIRIT trial and for men with metastatic CRPC as part of the Phase 3 SYNERGY trial. Enrollment in the ENSPIRIT trial is ongoing and top-line survival results from SYNERGY are expected by mid-2014.
Recent ACHV News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:39:30 PM
- Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors • GlobeNewswire Inc. • 08/26/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:11:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:07:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:05:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:08:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:06:08 PM
- Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update • GlobeNewswire Inc. • 08/13/2024 08:01:00 PM
- Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence • GlobeNewswire Inc. • 07/31/2024 12:00:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 12:10:11 PM
- Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024 • GlobeNewswire Inc. • 07/09/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/09/2024 04:15:14 AM
- Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:07:23 PM
- Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/20/2024 09:01:27 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/17/2024 06:56:31 PM
- Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting • GlobeNewswire Inc. • 05/17/2024 12:00:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:41 PM
- Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 08:01:28 PM
- Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine • GlobeNewswire Inc. • 05/06/2024 03:16:04 PM
- Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM